Iopromide Injection

• • Ultravist injection, Bayer, 300 mg iodine/ mL, 125 mL vial, 1 count, NDC 50419-0344-12
  • Ultravist injection, Bayer, 300 mg iodine/ mL, 50 mL vial, 1 count, NDC 50419-0344-05
  • Ultravist injection, Bayer, 370 mg iodine/ mL, 200 mL vial, 1 count, NDC 50419-0346-20
  • Ultravist injection, Bayer, 370 mg iodine/ mL, 50 mL vial, 1 count, NDC 50419-0346-05

• • Iohexol (Omnipaque - GE Healthcare) injection is currently in shortage due to the shutdown of a production facility in Shanghai, China during a COVID-19 lockdown. The facility is open again and production is operating at full capacity. As a result of the iohexol shortage, other contrast agents may be affected as organizations seek suitable alternatives. Additional information can be found at https://www.ge.com/news/press-releases/ge-healthcare-update-on-iodinated-contrast-media
  • Ultravist is sold through McKesson Specialty.

• • Ultravist injection, Bayer, 300 mg iodine/ mL, 100 mL vial, 1 count, NDC 50419-0344-10
  • Ultravist injection, Bayer, 300 mg iodine/ mL, 150 mL vial, 1 count, NDC 50419-0344-15
  • Ultravist injection, Bayer, 370 mg iodine/ mL, 100 mL vial, 1 count, NDC 50419-0346-10
  • Ultravist injection, Bayer, 370 mg iodine/ mL, 150 mL vial, 1 count, NDC 50419-0346-15

Estimated Resupply Dates

• • Bayer has Ultravist 300 mg of iodine/mL in 50 mL and 125 mL vials and 370 mg of iodine/mL in 50 mL and 200 mL vials on back order and the company cannot estimate release dates.

Alternative Agents & Management

• • More information can be found at Considerations for Imaging Contrast Shortage Management and Conservation
  • The American College of Radiology (ACR) has issued a statement addressing the shortage of iodinated contrast media. https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Contrast-Media-Shortage